Summary
The Trump administration extended its Medicaid low-price model on September 1, 2026, adding mid-cap biotechs to a program previously limited to large pharmaceutical companies. Manufacturers sign pricing agreements in exchange for formulary access. Consequently, what was once a large-company dynamic now applies to a broader segment of the industry. These agreements are not expected to materially affect revenue — but they carry structural implications for market access that deserve careful scrutiny.
Access Impact
The expansion signals a shift in how the US government approaches formulary positioning. Pricing is now being established through political negotiation rather than independent evidence review. The MARA domains most exposed are Budget Impact and Cost-Effectiveness. When a price is set before the evidence is formally assessed, manufacturers lose a key anchor for future negotiations. Moreover, the voluntary nature of these agreements creates competitive pressure: once larger peers have signed, mid-cap companies face implicit formulary risk if they decline.
Budget Impact
Medicaid formulary decisions directly affect payer budget calculations. However, a price commitment made through a White House agreement does not carry the same analytical weight as a structured budget impact model submitted through an HTA process. Manufacturers who accept these terms without a parallel evidence review risk locking in a price that cannot be supported by independent cost-effectiveness data. Specifically, if ICER or another body subsequently publishes an assessment, the prior Medicaid price may be used as a cost anchor in ways the manufacturer did not anticipate.
Cost-Effectiveness
The low-price model assumes value is implicit in the concession. It is not. Cost-effectiveness depends on clinical outcomes, comparator selection, and real-world effectiveness data — none of which are addressed in pricing agreements of this kind. As a result, a drug that receives favorable Medicaid pricing may still face scrutiny from health economists evaluating its cost per QALY. The signal created by these agreements is political, not evidentiary.
Evidence Quality
The absence of a structured evidence review is a significant gap. HTA bodies in the EU and UK require manufacturers to submit clinical and economic evidence before a pricing or reimbursement decision is issued. The US Medicaid low-price model bypasses this requirement entirely. For manufacturers operating globally, this creates precedent risk: a price agreed in the US without evidence support can be cited by payers in other markets as a reference baseline.
Risk Signal
Pricing without evidence is a liability in disguise. For mid-cap biotechs with limited portfolios and high revenue concentration in individual assets, a Medicaid pricing commitment that undermines future HTA negotiations carries disproportionate risk. Every market access team should ask one question before signing: if this price is challenged by an HTA body in two years, what independent, defensible evidence do we have to support it? Without an external benchmark, the answer is structural groupthink.
#MarketAccess #DrugPricing #Medicaid #MARArating
Explore market access risk standards: https://mararating.com/market-access-pharma/
Explore MARA independent assessments: https://mararating.com/mara-ratings-list